{"id":568865,"date":"2021-10-13T16:08:01","date_gmt":"2021-10-13T16:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=568865"},"modified":"2021-10-13T16:08:01","modified_gmt":"2021-10-13T16:08:01","slug":"irritable-bowel-syndrome-pipeline-drugs-companies-insight-report-2021-analysis-of-clinical-trials-therapies-moa-route-of-administration-and-developments","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/irritable-bowel-syndrome-pipeline-drugs-companies-insight-report-2021-analysis-of-clinical-trials-therapies-moa-route-of-administration-and-developments_568865.html","title":{"rendered":"Irritable Bowel Syndrome Pipeline Drugs & Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, MOA, Route of Administration, and Developments"},"content":{"rendered":"
\n
\"Irritable<\/a><\/div>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cIrritable Bowel Syndrome (IBS) – Pipeline Insight, 2021,\u201d report provides comprehensive insights about 24+ companies and 24+ pipeline drugs in the Irritable Bowel Syndrome (IBS) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s “Irritable Bowel Syndrome Pipeline Insight”<\/a> <\/strong>report provides comprehensive insights about key companies and pipeline drugs in the Irritable Bowel Syndrome pipeline landscapes. <\/p>\n

The report comprises Irritable Bowel Syndrome pipeline <\/a><\/strong>drug profiles, including clinical and non-clinical stage products. It also includes the Irritable Bowel Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Irritable Bowel Syndrome pipeline products.    <\/p>\n

\"\" <\/p>\n

Irritable Bowel Syndrome Overview<\/strong><\/p>\n

Irritable bowel syndrome is one of the most commonly diagnosed gastrointestinal diseases. Irritable Bowel Syndrome, in the absence of any other causative disease, is defined as the presence of abdominal pain or discomfort with altered bowel habits. The etiology of Irritable bowel syndrome is broad and not clearly understood. However, the pathophysiology of Irritable Bowel Syndrome is broad and includes abnormalities involving motility, visceral sensation, brain-gut interaction, and psychosocial distress. Irritable Bowel Syndrome typically consists of abdominal pain or discomfort, altered bowel habits along with either constipation, diarrhea, or both. Other complaints in patients with Irritable Bowel Syndrome include bloating, distention, symptoms brought on my food intake, and a change in pain location, and stool pattern with time. <\/p>\n

Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:<\/a><\/strong><\/p>\n